The aim of the present study was to investigate the long-term effectiveness of and tolerance to
Yttrium-90 and
Samarium-153-particulate hydroxyapatite radiation
synovectomy in patients with
rheumatoid arthritis (RA) and chronic knee
synovitis. Eight-four patients (90 knees) with chronic knee
synovitis and RA (according to the American College of Rheumatology criteria) participated in a controlled, double-blinded trial. Patients were randomized to receive an
intra-articular injection with either 5 mCi
Yttrium-90 plus 40 mg of
triamcinolone hexacetonide (Y/TH Group), 15 mCi
Samarium-153 hydroxyapatite plus 40 mg of
triamcinolone hexacetonide (Sm/TH Group), or 40 mg
triamcinolone hexacetonide alone (Control Group). Blinded examination at baseline, 1, 4, 12, 32, and 48 weeks post-intervention included a visual analog scale for
joint pain and swelling, morning stiffness, range of motion, knee circumference, Likert scale, percentage of improvement, Stanford Health Assessment Questionnaire, Lequesne index, use of non-steroidal anti-inflammatory drugs and
corticosteroids, events and adverse effects, calls to the physician, and hospital visits. There were three withdrawals prior to the
injections. Regarding the
pain, there was a significantly better response in the Y/TH Group versus the Sm/TH Group at T1 (p = 0.025) and versus TH alone at T48 (p = 0.026). The Sm/TH group had more adverse effects (p = 0.042), but these were mild and transitory. For the
pain parameter alone,
Yttrium-90 radiosynovectomy associated to TH proved superior to
Samarium-153 hydroxyapatite radiosynovectomy associated to TH at T1 and to
synovectomy with TH at T48. No other statistically significant inter-group differences were detected.